Rapamycin Target Eluting Coronary Stent System
It is the world’s innovative Rapamycin target eluting coronary stent system with real world outcomes, higher safety and efficacy and less drug dosage and more drug release control capability.
Targeted drug release towards Abluminal arterial wall fosters faster healing. It has conformal coated DES and in groove coated target eluting stent. Firehawk showcases high level RCT clinical trial proven workhorse stent with its outstanding 12-month performance in complex cases. Along with excellent early healing performance with 99.9% coverage rate at 3 months, it also shows proven safety in longer term.